Xencor, Inc. (XNCR)

Oncology Corporate Profile

Stock Performance


HQ Location

111 West Lemon Avenue
Monrovia, CA 91016

Company Description

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Currently, five antibodies are in clinical development internally and with partners that have been engineered with Xencor technology. Xencor internally-discovered programs include XmAb5871, in Phase 1b/2a clinical trials for the treatment of Rheumatoid arthritis and lupus, XmAb7195 in preclinical development for the treatment of asthma, and XmAb5574/MOR208 which has been licensed to Morphosys AG and is in Phase 2 clinical trials for the treatment of acute lymphoblastic leukemia and non-Hodgkin lymphoma.

Website: http://www.xencor.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
XmAb®5574anti-CD19 monoclonal antibody (humanized)Acute Lymphocytic Leukemia (ALL)IIMorphosys
XmAb®5574anti-CD19 monoclonal antibody (humanized)Chronic Lymphocytic Leukemia (CLL)IIMorphosys
XmAb®5574anti-CD19 monoclonal antibody (humanized)Non-Hodgkin's Lymphoma (NHL)IIMorphosys
XmAb®2513anti-CD30 monoclonal antibody (humanized)2nd line metastatic Hodgkin's LymphomaI
XmAb®14045anti-CD20 monoclonal antibodyAcute Myelogenous Leukemia (AML)I

View additional information on product candidates here »

Source: http://www.xencor.com

Recent News Headlines

Lenvatinib in Combination with Everolimus

5/16/2016 11:03 am

(FDA.gov) May 16, 2016 - On May 13, 2016, the U. S. Food and Drug Administration approved lenvatinib capsules (Lenvima, Eisai, Inc.), in combination with everolimus, for the treatment of advanced renal cell carcinoma following one prior anti-angiogenic therapy.

Is Colonoscopy The Gold Standard For Colorectal Cancer Screening?

3/14/2016 11:03 am

(STAT/Gut Check) Mar 14, 2016 - The Claim: Colonoscopy is far and away the best way to screen for colorectal cancer.

Gilead Cancer Drug Reviewed by EU After Deaths in Combo Trials

3/11/2016 12:03 pm

(Bloomberg) Mar 11, 2016 - European regulators are reviewing Gilead Sciences Inc.’s cancer drug Zydelig after some patients died or suffered other side effects while taking it with other drugs in clinical trials.

Depressed Head and Neck Cancer Patients Three-and-one-Half Times Less Likely to Survive, Have Higher Recurrence Risk

12/4/2015 11:02 am

(MD Anderson) Dec 3, 2015 - Depression is a significant predictor of five-year survival and recurrence in head and neck cancer patients, according to a new study from The University of Texas MD Anderson Cancer Center.

Anthracyclines Linked to Memory Problems in Breast Cancer

12/4/2015 11:02 am

(Medscape Medical News) Dec 3, 2015 - Anthracyclines might increase the risk for certain long-term memory problems and brain injury in patients with breast cancer, according to a small study published online December 3 in JAMA Oncology.

How To Wake A Sleeping Cancer Cell – And Why You Might Want To

12/4/2015 11:02 am

(Garvan Institute of Medical Research [Australia]) Dec 4, 2015 - Cancer cells can be ‘woken up’ when bone tissue is broken down around them, suggesting new possibilities for treating metastatic cancer in bone, according to Australian researchers.

‘Purity’ Of Tumor Samples May Significantly Bias Genomic Analyses

12/4/2015 11:02 am

(UCSF) Dec 4, 2015 - A new study by UC San Francisco scientists shows that the proportion of normal cells, especially immune cells, intermixed with cancerous cells in a given tissue sample may significantly skew the results of genetic analyses and other tests performed both by researchers and by physicians selecting precision therapies.

Genetic Mutations Differ Within A Single Tumor, Study Finds

12/4/2015 11:02 am

(U-M Health System) Dec 2, 2015 - When researchers looked at different areas within an individual rectal cancer sample, they found cases in which each area contained different genetic mutations.

Sun Pharma Gets FDA Approval for Generic of Novartis' Gleevec

12/4/2015 07:01 am

(Bloomberg) Dec 4, 2015 - Sun Pharmaceutical Industries Ltd., India’s largest drugmaker, said it received approval from the U.S. Food and Drug Administration to make a generic version of Novartis AG’s cancer drug Gleevec.

Cancer-Drug Prices Vary Widely Even Among Countries With Curbs

12/4/2015 07:00 am

(Bloomberg) Dec 3, 2015 - Even among countries with curbs on drug prices, the costs of cancer treatments vary widely, researchers wrote in the Lancet Oncology journal.

Obamacare and Drug Prices Push Health Spending to $3 Trillion

12/3/2015 11:05 am

(Washington Post/Wonkblog) Dec 2, 2015 - Health spending reached $3 trillion last year, as millions of people gained insurance coverage under the Affordable Care Act and prescription drug prices rose.

Merck CEO: In Healthcare, We Cannot Afford to Fail

12/3/2015 11:05 am

(Forbes/Guest Post) Dec 3, 2015 - Merck Chief Executive Kenneth Frazier is presenting this morning at the Forbes Healthcare Summit in New York. He submitted this piece in advance of his remarks.

NIH Isn’t Ensuring That Clinical Trials Account For Different Outcomes By Sex

12/3/2015 11:05 am

(Kaiser Health News) Dec 3, 2015 - Twenty-two years after Congress ordered the National Institutes of Health to include women in the clinical trials it funds to test medical treatments, women make up more than half the participants in those trials.

Congress Pressed by Sept. 11 First Responders to Extend Health Care, Compensation Benefits

12/3/2015 11:05 am

(U.S. & World News Report/Associated Press) Dec 3, 2015 - A day after undergoing chemotherapy, 9/11 first responder Robert Digiovanni stood angrily outside Senate Majority Leader Mitch McConnell's office, railing about politics interfering with life-or-death issues.

Takeda Exec to Climb Mt. Kilimanjaro Alongside Blood Cancer Patients

12/3/2015 11:04 am

(Boston Business Journal/Bioflash blog) Dec 2, 2015 - A nine-day trek to the summit of the world’s tallest free-standing mountain is a feat for even the healthiest of athletes.

MACRA: Learn the Basics, Get Ready for a Post-SGR World

12/3/2015 11:04 am

(ASCO in Action) Dec 2, 2015 - ASCO will present a free webinar, "MACRA: Learn the Basics, Get Ready for a Post-SGR World," featuring a high-level overview of the Medicare Access and Chip Reauthorization Act of 2015 (MACRA) on Tuesday, Dec. 15, 2015 from 4 - 5:30 p.m. EST.

ASH Announces Inaugural Giuseppe Bigi Memorial Award in Hematopoiesis and Stem Cells

12/3/2015 11:04 am

(ASH) Dec 3, 2015 - The American Society of Hematology today announced that Marilena Ciciarello, PhD, of the University of Bologna will receive the inaugural ASH Giuseppe Bigi Memorial Award for Achievement in Hematopoiesis and Stem Cells for her research on the role of stem cells in leukemia initiation and progression.

A Radical Proposal For Bringing Down The Cost Of Cancer Drugs

12/3/2015 11:04 am

(Forbes) Dec 3, 2015 - Today at the Forbes Healthcare Summit in New York City, Peter Bach of Memorial Sloan Kettering Cancer Center reviewed his radical proposal: The prices of all cancer drugs, he said, should be directly tied to the benefits they offer.

FDA Approves New Treatment For Rare Form of Hemophilia

10/24/2014 07:00 am

(FDA.gov) Oct 24, 2014 - The U.S. Food and Drug Administration yesterday approved Obizur [Antihemophilic Factor (Recombinant), Porcine Sequence] for the treatment of bleeding episodes in adults with acquired hemophilia A (acquired Factor VIII [FVII] deficiency).

3 Win Joint Nobel Prize in Medicine

10/7/2013 12:01 pm

(New York Times) Oct 7, 2013 - Three Americans won the Nobel Prize in Physiology or Medicine Monday for discovering the machinery that regulates how cells transport major molecules in a cargo system that delivers them to the right place at the right time in cells.

MorphoSys and Xencor Provide Update on Phase 1/2a Trial in CLL/SLL for MOR208 (Xmab5574)

10/7/2013 11:05 am

(MarketWatch) Oct 7, 2013 - MorphoSys AG and US-based Xencor, Inc. today announced completion of the phase 1/2a clinical trial evaluating MOR208 (formerly XmAb®5574) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL/SLL).

Monoclonal Antibody with Xencor's High ADCC Fc Technology Enters Phase 2 Study in B-cell Acute Lymphoblastic Leukemia

4/26/2013 11:05 am

(Yahoo! Finance) Apr 26, 2013 - Xencor announced today that MorphoSys AG has dosed the first patient in a Phase 2 clinical trial of MOR208 in B-cell acute lymphoblastic leukemia (B-ALL).

Stomach Cancer Survival Rates Rise In Last Decade

7/2/2012 11:02 am

(Huffington Post UK) July 2, 2012 - The number of people surviving after treatment for oesophageal or stomach cancer has risen significantly in the last 10 years, according to new figures.

National Cancer Institute Senior Investigator Moves to the Cancer Prevention Institute of California

1/19/2012 12:00 pm

(San Francisco Chronicle) Jan 18, 2012 - Ann Hsing, Ph.D., M.P.H., has joined the Cancer Prevention Institute of California (CPIC) as its new Director of Research.